Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hisamitsu Invests 200 Million Yen in Kyushu Univ. Regenerative Medicine Startup
September 24, 2021
- KM Biologics Moves Up COVID-19 Vaccine Target, Aims for Rollout in FY2022
September 22, 2021
- Takeda Grabs Japan Rights to Mirum’s Rare Liver Disease Drug
September 22, 2021
- Shionogi President Calls for Approval Systems to Respond to Emergency Situations
September 22, 2021
- COVID-19 Antibody Cocktail Ronapreve Faces Tight Manufacturing Capacity Worldwide: Chugai Chairman
September 22, 2021
- New Heart Failure Drugs Jostling with Different Modes of Action, Offering Variety of Options
September 21, 2021
- Takeda to Offload Non-Core Assets in Latin America to Adium
September 21, 2021
- Takeda, Janssen to Wind Up Reminyl Collaboration in Japan
September 21, 2021
- New Probe Finds No Safety Issues with White Matter Detected in Pfizer Jab
September 21, 2021
- Enhertu Enters Chinese PII Study for 3rd Line Gastric Cancer
September 21, 2021
- World’s First CAR-T Clinical Trial for GM2 Solid Cancers Might Begin by Year-End
September 17, 2021
- Sumitomo Dainippon Expects Twymeeg’s Initial Uptake in Combo, but Eyes 1st Line Monotherapy Use Too
September 17, 2021
- EA Pharma Appoints Eisai Senior VP Hidenori Yabune as President
September 17, 2021
- Takeda’s Exkivity Gets US Nod for EGFR Exon 20-Mutant NSCLC
September 17, 2021
- J-TEC’s Oral Mucosal Cell Sheet Ocural Earns NHI Listing
September 16, 2021
- White Matter Found in COVID-19 Vaccine Vials Not Contaminant: Pfizer
September 16, 2021
- Heart Failure Med Verquvo Makes Japan Debut: Bayer
September 16, 2021
- Another Patient Dies in Astellas’ Gene Therapy Trial, FDA Issues New Clinical Hold
September 15, 2021
- Taiho Seeks Japan Approval for GIST Drug Pimitespib
September 15, 2021
- Keytruda Filed for RCC Adjuvant Therapy in Japan: MSD
September 15, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…